Trodelvy clinical trial results likely practice-changing for people with metastatic triple-negative breast cancer
Full article:

The ASCENT study confirmed an earlier study and showed that the drug sacituzumab govitecan-hizy (Trodelvy) improves outcomes for people with previously treated metastatic triple-negative breast cancer. These results further support the use of Trodelvy as a standard therapy for patients with pretreated metastatic triple-negative breast cancer. (11/20/20)

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are studies looking at new treatments for people with metastatic TNBC.  

A number of other clinical trials for treating patients with metastatic TNBC can be found here.

The following studies are looking at treatment for people with advanced solid tumors. 



FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.